Pathogenesis of calcific aortic valve stenosis;Pathogenese der kalzifizierenden aortenklappenstenose

Herz

Volumn 31, Issue 7, 2006, Pages 620-628

  Kaden, Jens J ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b I Medizinische Klinik   (Germany)

Author keywords

Biomineralization; Calcific aortic valve stenosis; Matrix remodeling

Indexed keywords

AORTA VALVE STENOSIS; ARTERY CALCIFICATION; BIOMINERALIZATION; CARDIOVASCULAR RISK; HEART VALVE REPLACEMENT; HUMAN; NONHUMAN; PATHOGENESIS; PREVALENCE; REVIEW; TISSUE DEGENERATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ANTILIPEMIC AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; CONTROLLED CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MALE; MIDDLE AGED; MINERALS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 33750535639     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-006-2888-5     Document Type: Review

References (101)

1. Andreasen JJ, Farholt S, Jensen JS. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. APMIS 1998;106:717-20.
2. Antonini-Canterin F, Zuppiroli A, Baldessin F, et al. Is there a role of statins in the prevention of aortic biological prostheses degeneration. Cardiovasc Ultrasound 2006;4:26.
3. Aronow WS, Ahn C, Kronzon I, et al. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001;88:693-5.
4. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987;159:998-9.
5. Bellamy MF, Pellikka PA, Klarich KW, et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002;40:1723-30.
6. Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006;47:1707-12.
7. Conca W, Kaplan PB, Krane SM. Increases in levels of procollagenase mRNA in human fibroblasts induced by interleukin-1, tumor necrosis factor-alpha, or serum follow c-jun expression and are dependent on new protein synthesis. Trans Assoc Am Physicians 1989;102:195-203.
8. Corcoran GM, Prayson RA, Herzog KM. The significance of perivascular inflammation in the absence of arteritis in temporal artery biopsy specimens. Am J Clin Pathol 2001;115:342-7.
9. Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995;270:13453-9.
10. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
11. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterinaemia among patients with calcific aortic stenosis. J Chronic Dis 1984;37:407-15.
12. Drolet MC, Arsenault M, Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 2003;41:1211-7.
13. Edep ME, Shirani J, Wolf P, et al. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000;9:281-6.
14. Engelse MA, Neele JM, Bronckers AL, et al. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovasc Res 2001;52:281-9.
15. Galante A, Pietroiusti A, Vellini M, et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 2001;38:1078-82.
16. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994;75:181-9.
17. Galis ZS, Muszynski M, Sukhova GK, et al. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995;748:501-7.
18. Glader CA, Birgander LS, Soderberg S, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J 2003;24:198-208.
19. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995;76:928-32.
20. Grayston JT, Campbell LA, Kuo CC, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990;161:618-25.
21. Hayakawa T, Yamashita K, Ohuchi E, et al. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-9.
22. Higuchi ML, Higuchi-Dos-Santos MH, Pierri H, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in calcified nodules of aortic stenotic valves. Rev Inst Med Trop Sao Paulo 2002;44:209-12.
23. Hilti P, Jander N, Murtin C, et al. Is Chlamydia pneumoniae aetiologically linked to aortic stenosis? Eur Heart J 1999;20:Suppl:598.
24. Hoagland PM, Cook EF, Flatley M, et al. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol 1985;55:744-7.
25. Jian B, Jones PL, Li Q, et al. Matrix metalloproteinase-2 is associated with tenascin-c in calcific aortic stenosis. Am J Pathol 2001;159:321-7.
26. Jian B, Narula N, Li QY, et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003;75:457-65, discussion 465-6.
27. Juvonen J, Juvonen T, Laurila A, et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann Intern Med 1998;128:741-4.
28. Juvonen T, Juvonen J, Savolainen MJ. Is vasculitis a significant component of atherosclerosis? Curr Opin Rheumatol 1999;11:3-10.
29. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis - immunohistochemistry study and review of the literature. J Heart Valve Dis 2003;12:447-53.
30. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Receptor activator of nuclear factor kappa B ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 2004;36:57-66.
31. Kaden JJ, Bickelhaupt S, Grobholz R, et al. Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis. J Heart Valve Dis 2004;13:560-6.
32. Kaden JJ, Dempfle CE, Grobholz R, et al. Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic stenosis. Atherosclerosis 2003;170:205-11.
33. Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005;14:80-7.
34. Kaden JJ, Dempfle CE, Kilic R, et al. Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp Mol Pathol 2005;78:36-40.
35. Kaden JJ, Haghi D, Vocke DC, et al. Chlamydia pneumoniae - ein neuer Risikofaktor bei kalzifizierender Aortenstenose? Med Klin 2005;100:334-9.
36. Kaden JJ, Kilic R, Sarikoc A, et al. Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification. Int J Mol Med 2005;16:869-72.
37. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-23.
38. Lee YS, Chou YY. Pathogenetic mechanism of senile calcific aortic stenosis: the role of apoptosis. Chin Med J (Engl) 1998;111:934-9.
39. Le Gal G, Bertault V, Bezon E, et al. Heterogeneous geographic distribution of patients with aortic valve stenosis: arguments for new aetiological hypothesis. Heart 2005;91:247-9.
40. Lindroos M, Kupari M, Heikkila J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993;21:1220-5.
41. Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994;15:865-70.
42. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 2000;192:463-74.
43. Mohler ER 3rd, Adam LP, McClelland P, et al. Detection of osteopontin in calcified human aortic valves. Arterioscler Thromb Vasc Biol 1997;17:547-52.
44. Mohler ER 3rd, Chawla MK, Chang AW, et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis 1999;8:254-60.
45. Mohler ER 3rd, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation 2001;103:1522-8.
46. Mohler ER, Sheridan MJ, Nichols R, et al. Development and progression of aortic valve stenosis: atherosclerotic risk factors - a causal relationship? Clin Cardiol 1991;14:995-9.
47. Mönckeberg JG. Der normale histologische Bau und die Sklerose der Aortenklappen. Virchows Arch Pathol Anat 1904;176:472-514.
48. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
49. Nakagawa N, Kinosaki M, Yamaguchi K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998;253:395-400.
50. Novaro GM, Sachar R, Pearce GL, et al. Association between apolipoprotein E alleles and calcific valvular heart disease. Circulation 2003;108:1804-8.
51. Novaro GM, Tiong IY, Pearce GL, et al. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001;104:2205-9.
52. Nyström-Rosander C, Thelin S, Hjelm E, et al. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1997;29:361-5.
53. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation 1995;92:2163-8.
54. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
55. O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation 2002;106:2224-30.
56. Olsson M, Dalsgaard CJ, Haegerstrand A, et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994;23:1162-70.
57. Olsson M, Rosenqvist M, Nilsson J. Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis. J Ann Coll Cardiol 1994;24:1664-71.
58. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19:1218-22.
59. Ortlepp JR, Hoffmann R, Ohme F, et al. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart 2001;85:635-8.
60. Ortlepp JR, Pillich M, Mevissen V, et al. APOE alleles are not associated with calcific aortic stenosis. Heart 2006:in press.
61. Heart 2006;92:1463-6.
62. Ortlepp JR, Schmitz F, Bozoglu T, et al. Cardiovascular risk factors in patients with aortic stenosis predict prevalence of coronary artery disease but not of aortic stenosis: an angiographic pair matched case-control study. Heart 2003;189:1019-22.
63. Ortlepp JR, Schmitz F, Mevissen V, et al. The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis. Eur Heart J 2004;25:514-22.
64. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of "degenerative" valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53.
65. Pate GE, Tahir MN, Murphy RT, et al. Anti-inflammatory effects of statins in patients with aortic stenosis. J Cardiovasc Pharmacol Ther 2003;8:201-6.
66. Perez-Ramos J, de Lourdes Segura-Valdez M, Vanda B, et al. Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am J Respir Crit Care Med 1999;160:1274-82.
67. Pohle K, Mäffert R, Ropers D, et al. Progression of aortic valve calcification. Association with coronary artery atherosclerosis and cardiovascular risk factors. Circulation 2001;104:1927-32.
68. Pomerance A, Darby AJ, Hodkinson HM. Valvular calcification in the elderly: possible pathogenic factors. J Gerontol 1978;33:672-5.
69. Preaux AM, Mallat A, Nhieu JT, et al. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999;30:944-50.
70. Probst V, Le Scouarnec S, Legendre A, et al. Familial aggregation of calcific aortic valve stenosis in the western part of France. Circulation 2006;113:856-60.
71. Radke PW, Ortlepp JR, Merkelbach-Bruse S, et al. Prevalence of Chlamydia pneumoniae in non rheumatic stenotic aortic valves. Am Heart J 2002;144:E12.
72. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107:2181-4.
73. Rajamannan NM, Subramaniam M, Springett M, et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation 2002;105:2660-5.
74. Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91:806-10.
75. Rayger C. Anatome hominis subito extincti, cujus valvulae semilunares, ad aortae ostium sitae, osseae repertae sunt. In: Bonet T, ed. Sepulchretum sive anatomia practica. Genève: Chouet, 1679:702.
76. Robicsek F, Thubrikar MJ. Etiology of degenerative disease of the tri-leaflet aortic valve: a simple explanation for a complex problem. Z Kardiol 2001;90:Suppl 6:35-8.
77. Rose AG. Failure to detect Chlamydia pneumoniae in senile calcific aortic stenosis or calcified congenital bicuspid aortic valve by immunofluorescence, polymerase chain reaction and electron microscopy. Cardiovasc Pathol 2002;11:300-4.
78. Rosenhek R. Statins for aortic stenosis. N Engl J Med 2005;352:2441-3.
79. Rosenhek R, Binder T, Porenta G. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611-7.
80. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M, Binder T, Maurer G, Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 2004;110:1291-5.
81. Rossi MA, Santos CS, Corcoran GM, et al. Sepsis-related microvascular myocardial damage with giant cell inflammation and calcification. Virchows Arch 2003;443:87-92.
82. Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002;359:1125-6.
83. Shioi A, Katagi M, Okuno Y, et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-alpha and oncostatin M derived from macrophages. Circ Res 2002;91:9-16.
84. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19.
85. Skowasch D, Schrempf S, Lentini S, et al. Chlamydia pneumoniae und Zytomegalie-Virus in degenerativen Aortenklappenstenosen. Z Kardiol 2002;91:290-6.
86. Soini Y, Satta J, Maatta M, et al. Expression of MMP2, MMP9, MT1-MMP, TIMP1, and TIMP2 mRNA in valvular lesions of the heart. J Pathol 2001;194:225-31.
87. Srivatsa SS, Harrity PJ, Maercklein PB, et al. Increased cellular expression of matrix proteins that regulate mineralisation is associated with calcification of native human and procine xenograft bioprosthetic heart valves. J Clin Invest 1997;99:996-1009.
88. Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001;89:1147-54.
89. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
90. Taipale J, Saharinen J, Hedman K, et al. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem 1996;44:875-89.
91. Takahara T, Furui K, Yata Y, et al. Dual expression of matrix metalloproteinase-2 and membrane-type i-matrix metalloproteinase in fibrotic human livers. Hepatology 1997;26:1521-9.
92. Tanaka K, Sata M, Fukuda D, et al. Age-associated aortic stenosis in apolipoprotein E-deficient mice. J Am Coll Cardiol 2005;46:134-41.
93. Theret N, Lehti K, Musso O, et al. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 1999;30:462-8.
94. Thubrikar MJ, Aouad J, Nolan SP. Patterns of calcific deposits in operatively excised stenotic or purely regurgitant aortic valves and their relation to mechanical stress. Am J Cardiol 1986;58:304-8.
95. Tintut Y, Patel J, Parhami F, et al. Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 2000;102:2636-42.
96. Traub O, Berk BC. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler Thromb Vasc Biol 1998;18:677-85.
97. Tunick PA, Freedberg RS, Kronzon I. Cardiac findings in the very elderly: analysis of echocardiography in fifty-eight nonagenarians. Gerontology 1990;36:206-11.
98. Vainio K, Vengen O, Hoel T, et al. Failure to detect Chlamydia pneumoniae in aortic valves and peripheral blood mononuclear cells from patients undergoing aortic valve replacement in Norway. Scand J Infect Dis 2002;34:660-3.
99. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-54.
100. Wong BR, Rho J, Arron J, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 1997;272:25190-4.
101. Zand T, Majno G, Nunnari JJ, et al. Lipid deposition and intimal stress and strain. A study in rats with aortic stenosis. Am J Pathol 1991;139:101-13.